QPRT Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant QPRT.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC, E |
---|---|
Primary Accession | Q15274 |
Other Accession | NM_014298 |
Reactivity | Human |
Host | mouse |
Clonality | Monoclonal |
Isotype | IgG1 Kappa |
Clone Names | 5D11 |
Calculated MW | 30846 Da |
Gene ID | 23475 |
---|---|
Other Names | Nicotinate-nucleotide pyrophosphorylase [carboxylating], Quinolinate phosphoribosyltransferase [decarboxylating], QAPRTase, QPRTase, QPRT |
Target/Specificity | QPRT (NP_055113, 198 a.a. ~ 297 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | QPRT Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a key enzyme in catabolism of quinolinate, an intermediate in the tryptophan-nicotinamide adenine dinucleotide pathway. Quinolinate acts as a most potent endogenous exitotoxin to neurons. Elevation of quinolinate levels in the brain has been linked to the pathogenesis of neurodegenerative disorders such as epilepsy, Alzheimer's disease, and Huntington's disease.
References
1.QPRT: a potential marker for follicular thyroid carcinoma including minimal invasive variant; a gene expression, RNA and immunohistochemical study.Hinsch N, Frank M, Doring C, Vorlander C, Hansmann ML.BMC Cancer. 2009 Mar 26;9:93.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.